There was a sizeable increase in the number of short positions taken on Alnylam Pharmaceuticals, INC during February.
There were a total of 5,390,000 shares available for a short sale as of February 28.
This figure represents a 5.7% increase compared to the total number of 5,100,000 shares available the day before.
The current short-interest ratio is 7.0 days, based on an average daily volume of 775,000 shares.
This number was arrived at using the data.
When trading started on Thursday, the share price of ALNY was $185.75 per share.
The debt-to-equity ratio is 3.85, the current ratio is 3.51, and the quick ratio is 3.34.
All of these figures are presented in the following table: During the previous year, the price of Alnylam Pharmaceuticals fluctuated between $117.58 and $242.97 at various points.
The price as of right now is $117.58.
The simple moving average for the past 50 days of the company’s stock price is $215.55, and the simple moving average for the past 200 days is $213.71.
The company has a price-to-earnings ratio of -19.99, a market value equal to $23.06 billion, and a beta equal to 0.49.
Alnylam Pharmaceuticals (NASDAQ: ALNY) provided notice on Thursday, February 23, that it would be publishing the results report for the company’s most recent fiscal quarter.
The biopharmaceutical company reported earnings per share (EPS) of $1.68 for the quarter, which was $0.45 higher than the prediction of $2.13% made by the industry experts’ average.
The EPS figure was also higher than the average of the predictions made by the industry experts.
Alnylam Pharmaceuticals’s return on equity and net margin were below zero, coming in at a negative 1.287.80% and a negative 109.04 percent, respectively. Neither metric was profitable for the company.
The revenue for the quarter came in at $335.04 million, which was significantly higher than the analysts’ average estimate of $312.45 million for the revenue generated quarter.
In the prior year, the company posted earnings of $2.16 per share during the same period. Compared to the previous year, the corporation’s revenue experienced a significant increase of 29.6%.
The financial experts’ projections indicate that Alnylam Pharmaceuticals will finish the current fiscal year with a loss in earnings of 6.85 cents per share in the company’s common stock.
In additional related news, on February 2, 1,675 shares of Alnylam Pharmaceuticals stock were sold by Indrani Lall Franchini, the executive vice president of Alnylam Pharmaceuticals.
A total price of $378,566.75 was received for the sale of the shares, which works out to an average selling price of $226.01 per share. Following the completion of the acquisition, the executive vice president was able to purchase 3,500 shares of the company, which had a combined value of $791,035. On the Securities and Exchange Commission’s (SEC) website, you can access the information submitted to the SEC regarding the transaction, which is currently available.
The company’s Chief Marketing Officer, Pushkal Garg, sold 18,072 shares of the company’s stock on Friday, March 3. Related developments can be found here.
The cost per share was determined to be an average of $200.00, resulting in the transaction’s total value of $3,614,400.00.
The chief marketing officer is the direct owner of 4,345 shares of the company as of right now, and the total value of those shares is $869,000. Following this link will take you to a document submitted to the Securities and Exchange Commission (SEC).
The document contains an in-depth explanation of the transaction that was reported to the SEC.
In related news, Indrani Lall Franchini, Executive Vice President of Alnylam Pharmaceuticals, sold 1,675 shares on February 2.
A total price of $378,566.75 was received for the sale of the shares, which works out to an average selling price of $226.01 per share.
The transaction has directly resulted in the executive vice president gaining ownership of 3,500 shares of company stock, which have a combined value of $791,035.
The disclosure about the purchase can be found in this particular location.
The company’s insiders hold a total of 1.40 percent of the company’s shares.
Recently, several institutional investors adjusted the overall quantity of shares of stock that were held within their respective portfolios. Within the investment portfolio that Raymond James Financial Services Advisors, INC manages, the percentage of Alnylam Pharmaceuticals shares held at the end of the first quarter increased by 9.4%.
There are currently 11,850 shares of the biopharmaceutical company owned by Raymond James Financial Services Advisors INC These shares are currently valued at $1,935,000.
This is a direct consequence of the company acquiring 1,017 additional shares during the most recent fiscal quarter.
During the first three months of 2018, MetLife Investment Management LLC made a new investment in Alnylam Pharmaceuticals.
The cost of this investment was approximately $1,268,000 for the company.
Panagora Asset Management INC increased the percentage of ownership it held in Alnylam Pharmaceuticals by 96.4% over the first three months of 2018.
After purchasing an additional 3,223 shares during the most recent quarter, Panagora Asset Management INC now has 6,565 shares of the biopharmaceutical company’s stock, currently valued at $1,072,000.
During the most recent quarter, these shares were acquired. Great West Life Assurance Company of Canada increased the amount of Alnylam Pharmaceuticals stock owned by 21.2% over the first three months of 2018.
After making an additional 10,892 share purchase during the most recent quarter, Great West Life Assurance Co now owns 62,369 shares of the biopharmaceutical company.
The current value of these shares, when traded on the market, is $10,786,000.
And finally, during the first three months of this year, Dimensional Fund Advisors LP increased the number of shares of Alnylam Pharmaceuticals owned by 1.2%. Following the purchase of 2,111 additional shares of the biopharmaceutical company during the most recent fiscal quarter, Dimensional Fund Advisors LP now has 181,271 shares of ownership.
There is a value of $29,601,000 attached to these shares.
Recent commentary on the stock comes from analysts who focus on equity research and have recently shared their perspectives. JPMorgan Chase & Co decreased their price target on Alnylam Pharmaceuticals shares from $200.00 to $196.00 and gave the company a “neutral” rating in a report published on Friday, March 3. Needham & Company LLC reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report published on Friday, February 24.
The firm also established a target price of $240.00 for the company’s stock at the time of the report’s publication.
In a research note published on February 21, the EF Hutton Acquisition Co and I started covering shares of Alnylam Pharmaceuticals.
They suggested investing in the company’s stock and setting the target price at $304.00 per share for this investment. Chardan Capital reaffirmed its “buy” rating on shares of Alnylam Pharmaceuticals and set a target price of $250.00 for the company’s stock in a research report published on Friday, February 24.
The report was about the company’s stock.
Piper Sandler gave Alnylam Pharmaceuticals an “overweight” rating in a research note published on Friday, December 16.
In addition, the brokerage firm raised its price objective for the company’s stock from $226.00 to $253.00.
In addition to that, they increased their price objective for the stock from $226.00 to $253.00. Seven market analysts suggest that the stock should be held in one’s portfolio, while fourteen others suggest that the stock should be purchased.
The information provided by Bloomberg indicates that the consensus regarding Alnylam Pharmaceuticals is currently a “Moderate Buy,” and the consensus regarding its price objective is $244.26.